天士力(600535.SH):藿香正氣滴丸入選新型冠狀病毒感染的肺炎診療方案(試行第五版)
格隆匯2月5日丨天士力(600535.SH)公佈,近日有投資者關注公司部分產品情況,現將相關情況説明如下:
公司產品藿香正氣滴丸2018年度實現銷售收入約為1.36億元,約佔公司2018年度醫藥工業營業收入的1.91%。公司無其他藿香正氣相關製劑產品。從全國城市零售藥店來看,2018年度藿香正氣製劑的市場容量為近20億,公司藿香正氣滴丸市場份額為13.89%(數據來源:米內)。國家衞生健康委、國家中醫藥管理局印發《新型冠狀病毒感染的肺炎診療方案(試行第五版)》中醫治療方案提及“臨牀表現1:乏力伴腸胃不適推薦中成藥:藿香正氣膠囊(丸、水、口服液)”。相關事項預計不會對公司業績產生重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.